Filing and reporting period
Important filing-identity discrepancy: The request identifies ACCENDRA HEALTH INC, but the supplied Form 10-K is for Owens & Minor, Inc. This summary covers the filing provided, not Accendra Health. It reports the year ended December 31, 2015; the filing is an annual report, not a standalone fourth-quarter filing.
Owens & Minor provides healthcare product distribution, kitting, and logistics services through Domestic and International segments. Its 2014 acquisitions of Medical Action and ArcRoyal expanded its surgical kitting business.
Key financial results
| Metric | 2015 | 2014 | Change |
|---|---|---|---|
| Net revenue | $9.773 billion | $9.440 billion | +3.5% |
| Gross margin | $1.215 billion; 12.43% of revenue | $1.170 billion; 12.39% | +3.8%; +4 bps |
| Operating earnings, GAAP | $200.4 million; 2.05% of revenue | $159.5 million; 1.69% | +25.6% |
| Net income | $103.4 million | $66.5 million | +55.5% |
| Diluted EPS | $1.65 | $1.06 | +$0.59 |
| Adjusted EPS (non-GAAP) | $2.00 | $1.76 | +13.6% |
| Cash from operations | $269.6 million | $(3.8) million | Improved by $273.4 million |
Adjusted operating earnings were $227.3 million, or 2.33% of revenue, versus $202.5 million, or 2.15%, in 2014. Adjusted figures exclude specified acquisition, exit and realignment, purchase-accounting, contract-settlement, and debt-retirement items; they are management-defined non-GAAP measures.
At year-end, cash was $161.0 million, total debt was $577.6 million, and shareholders’ equity was $992.6 million. The $450 million revolving facility had no borrowings and approximately $445 million available after letters of credit. Current assets were $1.975 billion and current liabilities $1.064 billion. Capital expenditures were $36.6 million. Dividends paid were $63.7 million; share repurchases were $20.0 million.
Changes versus prior year and segment trends
- Domestic revenue rose 4.5% to $9.356 billion; segment operating earnings increased to $223.4 million from $209.3 million. Growth in large provider accounts, Medical Action, manufacturer price changes, expense controls, and lower fuel costs contributed.
- International revenue fell 14.6% to $416.8 million, including a $52.5 million adverse currency translation effect. On the company’s stated adjusted comparison basis, revenue declined approximately 3.5%, reflecting a U.K. contract exit and other lost business. Segment operating results improved to $3.9 million from a $6.7 million loss, attributed to restructuring and efficiency measures.
- Operating cash flow rebounded from negative $3.8 million in 2014, aided by higher earnings and favorable working-capital timing, particularly vendor payments. Inventory rose 7.8%, while accounts payable rose 16.7%; inventory turnover declined from 10.1 to 9.4.
- Interest expense increased 49.5% to $27.1 million, primarily following the 2014 issuance of senior notes. The effective tax rate decreased to 40.3% from 47.4%.
Outlook, risks, and unusual items
- Management said it expected approximately $20 million of acquisition-related and exit/realignment charges in 2016 for activities to be undertaken in both segments. Separately, the notes state that significant additional costs were not expected for activities initiated through year-end 2015.
- Management believed cash generation and available credit would fund working capital, capital spending, debt service, dividends, repurchases, and other foreseeable needs. It anticipated continued quarterly dividends; the board approved a first-quarter 2016 dividend of $0.255 per share, up 1% from the 2015 quarterly rate.
- Key exposures include intense distribution pricing pressure; reliance on major GPOs, provider customers, and suppliers; customer and supplier consolidation; healthcare-policy and reimbursement changes; foreign exchange and European market conditions; regulatory, privacy, cybersecurity, product-liability, and distribution-network risks.
- Approximately 81% of consolidated revenue came from sales to hospitals under contract with Novation, MedAssets, and Premier. The top ten U.S. customers represented about 29% of consolidated revenue; the ten largest domestic suppliers accounted for about 57%.
- 2015 included $28.4 million of acquisition-related and exit/realignment charges and a $1.5 million insurance recovery tied to a U.K. contract settlement. GAAP results also compare against a 2014 year that included a $14.9 million loss on early debt retirement.
- Pending legal matters were described as ordinary and incidental; the company said probable-loss accruals were not material and did not expect current matters to materially affect results. The financial-statement audit opinion was unqualified, and management and the auditor reported effective internal control over financial reporting.
Important facts for investors to verify
- Confirm the issuer: the supplied filing is Owens & Minor, Inc., not ACCENDRA HEALTH INC.
- Review the full filing’s segment disclosures and the basis for International revenue comparisons, including currency translation, acquisitions, contract exits, and the buy-sell-to-fee-for-service transition.
- Assess whether cash-flow improvement is sustainable, given the stated working-capital timing benefit and the increase in accounts payable.
- Track the expected 2016 restructuring charges and reconcile planned new actions with the disclosure about costs for previously initiated activities.
- Evaluate concentration and contract-renewal risks involving GPOs, large customers, and significant suppliers, along with debt maturities, covenants, and fixed lease commitments.
- Compare GAAP performance with management’s non-GAAP adjustments and review the associated reconciliation before relying on adjusted EPS.